Rani Therapeutics Holdings, Inc. Class A (RANI)

Rani Therapeutics Holdings, Inc. stock price has increased significantly by 254.88% in the past six months. Key events include equity offerings raising approximately $20 million, an oversubscribed $60.3 million private placement agreement, a collaboration agreement with Chugai Pharmaceutical potentially worth up to $1.085 billion, positive preclinical pharmacokinetic data for its GLP-1 incretin triagonist with plans to commence a Phase 1 study for RT-114 in 2025, and earnings reports for Q3 2025, Q2 2025, and Q1 2025. An Annual General Meeting was held on May 28, 2025.

Rani Therapeutics Holdings, Inc. does not typically experience demand seasonality. The demand for its products and services is primarily driven by the progression of its clinical pipeline, regulatory approvals, and the unmet medical needs its therapies aim to address.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on transforming drug administration from injections to oral pills, operating in the Biotechnology industry. Its core technology is the RaniPill™ capsule, an oral delivery platform for various drug substances. The company's product pipeline includes RT-101 for neuroendocrine tumors and acromegaly, RT-102 for osteoporosis, RT-105 for psoriatic arthritis, RT-106 for type 2 diabetes, RT-109 for growth hormone deficiency, RT-110 for hypoparathyroidism, RT-111 for inflammatory conditions, RT-114 for obesity (with a Phase 1 study planned in 2025), and RT-116 for obesity.

Rani Therapeutics Holdings, Inc. is headquartered in San Jose, California, United States. The company aims to bring its oral biologic solutions to patients globally through strategic partnerships.

Rani Therapeutics' brand reputation has been positively influenced by a consensus "Strong Buy" rating from analysts, positive preclinical data for its RT-114, and the collaboration agreement with Chugai Pharmaceutical. Potential challenges include concerns regarding revenue forecasts, intense competition, the ability to secure necessary reimbursement levels, and the risk of failures in future clinical trials.

Rani Therapeutics Holdings, Inc. has a diverse ownership structure, with approximately 3.32% held by institutional shareholders, 33.62% by insiders, and 63.06% by retail investors. Major institutional owners include Vanguard Group Inc, Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), Nan Fung Group Holdings Ltd, Citadel Advisors Llc, United Services Automobile Association, Geode Capital Management, Llc, Vanguard Extended Market Index Fund Investor Shares (VEXMX), Kestra Private Wealth Services, Llc, Takeda Pharmaceutical Co Ltd, CWA Asset Management Group, LLC, RA Capital Management, L.P., Samsara BioCapital, L.P., and InCube Labs, L.L.C. Key individual owners and insiders include Mir A. Imran (owning 20.48% of the company), South Cone Investments Limited Partnership, Moreno Isidoro Quiroga, Talat Imran, and Andrew Farquharson.